{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:12:26Z","timestamp":1760573546366,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443297229"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.033","type":"book-chapter","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:43:53Z","timestamp":1747755833000},"page":"59-82","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcome measures"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2025.04.033_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.25539","article-title":"Electrophysiological testing is correlated with myasthenia gravis severity","volume":"56","author":"Abraham","year":"2017","journal-title":"Muscle &\u00a0Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/mus.25720","article-title":"The utility of a single simple question in the evaluation of patients with myasthenia gravis","volume":"57","author":"Abraham","year":"2018","journal-title":"Muscle &\u00a0Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib3","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"The REGAIN study group, eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"1998","journal-title":"Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"key":"10.1016\/bs.irn.2025.04.033_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.24911","article-title":"Validation of the besta neurological institute rating scale for myasthenia gravis","volume":"53","author":"Antozzi","year":"2016","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/ene.13836","article-title":"EQ\u20105D\u20105L and SF\u20106D health utility index scores in patients with myasthenia gravis","volume":"26","author":"Barnett","year":"2019","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1212\/WNL.0000000000002971","article-title":"Development and validation of the myasthenia gravis impairment index","volume":"87","author":"Barnett","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","article-title":"Measuring clinical treatment response in myasthenia gravis","volume":"36","author":"Barnett","year":"2018","journal-title":"Neurologic Clinics"},{"key":"10.1016\/bs.irn.2025.04.033_bib8","article-title":"The quantitative myasthenia gravis score: Comparison with clinical","volume":"13","author":"Barnett","year":"2012","journal-title":"Electrophysiological, and Laboratory Markers"},{"key":"10.1016\/bs.irn.2025.04.033_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score a","volume":"841","author":"Barohn","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.033_bib10","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/mus.25174","article-title":"Single fiber EMG as a prognostic tool in myasthenia gravis","volume":"54","author":"Baruca","year":"2016","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1749-6632.1981.tb33781.x","article-title":"Long\u2010term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis","volume":"377","author":"Besinger","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.033_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cnp.2024.06.004","article-title":"Using jitter analysis with concentric needle electrodes to assess disease status and treatment responses in myasthenia gravis","volume":"9","author":"Bhandari","year":"2024","journal-title":"Clinical Neurophysiology Practice"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.033_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: The MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle &\u00a0Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: A 15\u2010item quality\u2010of\u2010life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mus.21609","article-title":"Construct and concurrent validation of the MG\u2010QOL15 in the practice setting","volume":"41","author":"Burns","year":"2010","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2307\/3527467","article-title":"The WHO definition of \u201cHealth\u201d","volume":"1","author":"Callahan","year":"1973","journal-title":"Studies - Hastings Center"},{"key":"10.1016\/bs.irn.2025.04.033_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s13023-021-02064-0","article-title":"Development of the myasthenia gravis (MG) symptoms PRO: A case study of a patient-centred outcome measure in rare disease","volume":"16","author":"Cleanthous","year":"2021","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/bs.irn.2025.04.033_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11136-014-0790-9","article-title":"Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers","volume":"24","author":"Cook","year":"2015","journal-title":"Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation"},{"issue":"21","key":"10.1016\/bs.irn.2025.04.033_bib22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.033_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3233\/JND-200484","article-title":"Myasthenia gravis impairment index: Sensitivity for change in generalized muscle weakness","volume":"7","author":"De Meel","year":"2020","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1016\/bs.irn.2025.04.033_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/ene.13867","article-title":"Sensitivity of MG-ADL for generalized weakness in myasthenia gravis","volume":"26","author":"De Meel","year":"2019","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"Farrugia","year":"2006","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2025.04.033_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.21880","article-title":"The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients","volume":"43","author":"Farrugia","year":"2011","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mus.21156","article-title":"Correlating extent of neuromuscular instability with acetylcholine receptor antibodies","volume":"39","author":"Farrugia","year":"2009","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high\u2010dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.033_bib29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1212\/WNL.0000000000207278","article-title":"Addressing outcome measure variability in myasthenia gravis clinical trials","volume":"101","author":"Guptill","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.033_bib32","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.033_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib34","doi-asserted-by":"crossref","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): Interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","author":"Howard","year":"2017","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1212\/WNL.31.4.386","article-title":"Myasthenia gravis: Relation between jitter in single\u2010fiber EMG and antibody to acetylcholine receptor","volume":"31","author":"Konishi","year":"1981","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.033_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0896-8411(91)90018-8","article-title":"Anti-acetylcholine receptorantibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations","volume":"4","author":"Kuks","year":"1991","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.033_bib38","first-page":"449","article-title":"Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1016\/bs.irn.2025.04.033_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti\u2010acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1187189","article-title":"Time to achieve a patient acceptable symptom state in myasthenia gravis","volume":"14","author":"Martinez-Harms","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.033_bib41","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib42","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010574","article-title":"Patient-acceptable symptom states in myasthenia gravis","volume":"95","author":"Mendoza","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.27243","article-title":"Telephone consultation for myasthenia gravis care during the COVID\u221219 pandemic: Assessment of a novel virtual myasthenia gravis index","volume":"63","author":"Menon","year":"2021","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004691-200309000-00011","article-title":"Single fiber EMG as an outcome measure in myasthenia gravis: Results from a double-blind, placebo-controlled trial","volume":"20","author":"Meriggioli","year":"2003","journal-title":"Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society"},{"key":"10.1016\/bs.irn.2025.04.033_bib45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease\u2010specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in myasthenia gravis: Incorporation into clinical practice","volume":"18","author":"Muppidi","year":"2017","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"10.1016\/bs.irn.2025.04.033_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mus.27443","article-title":"Identifying a patient\u2010centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis","volume":"65","author":"Narayanaswami","year":"2022","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.033_bib48","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"The Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.033_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib51","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1007\/s10072-022-05918-y","article-title":"Development and validation of the myasthenia gravis TeleScore (MGTS)","volume":"43","author":"Pasqualin","year":"2022","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.033_bib52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib53","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00415-016-8072-9","article-title":"Validation of the MG-DIS: A disability assessment for myasthenia gravis","volume":"263","author":"Raggi","year":"2016","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3109\/09638288.2013.804591","article-title":"Development of the MG-DIS: An ICF-based disability assessment instrument for myasthenia gravis","volume":"36","author":"Raggi","year":"2014","journal-title":"Disability and Rehabilitation"},{"key":"10.1016\/bs.irn.2025.04.033_bib55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12883-017-0891-5","article-title":"Single-fiber electromyography in the orbicularis oculi muscle in patients with ocular myasthenia gravis symptoms: Does abnormal jitter predict response to treatment?","volume":"17","author":"Rakocevic","year":"2017","journal-title":"BMC Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1368525","article-title":"Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis","volume":"15","author":"Regnault","year":"2024","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib57","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","article-title":"Guidelines for single fiber EMG","volume":"130","author":"Sanders","year":"2019","journal-title":"Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2025.04.033_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mus.25440","article-title":"Does change in neuromuscular jitter predict or correlate with clinical change in MG?","volume":"56","author":"Sanders","year":"2017","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A simple manual muscle test for myasthenia gravis: Validation and comparison with the QMG score","volume":"998","author":"Sanders","year":"2003","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2025.04.033_bib60","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.nmd.2020.07.006","article-title":"A new and easily used modified myasthenia gravis score","volume":"30","author":"Sathirapanya","year":"2020","journal-title":"Neuromuscular Disorders : NMD"},{"key":"10.1016\/bs.irn.2025.04.033_bib61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s004150050585","article-title":"Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis","volume":"247","author":"Sharshar","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk9109","article-title":"The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis","volume":"16","author":"Skov","year":"2024","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2025.04.033_bib63","article-title":"Serological markers of clinical improvement in MuSK myasthenia gravis","volume":"11","author":"Spagni","year":"2024","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/bs.irn.2025.04.033_bib64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards","volume":"55","author":"Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib65","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"The Muscle Study Group","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib66","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"The REGAIN study group","year":"2020","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome measures in clinical trials of patients with myasthenia gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.033_bib69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mus.26069","article-title":"Fatigue is a relevant outcome in patients with myasthenia gravis","volume":"58","author":"Tran","year":"2018","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"The Lancet. Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib71","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/mus.21142","article-title":"Comparison of outcome measures from a trial of Mycophenolate mofetil in myasthenia gravis","volume":"38","author":"Wolfe","year":"2008","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.033_bib72","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.033_bib74","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210150","article-title":"Multicenter validation of the ocular myasthenia gravis rating scale questionnaire","volume":"104","author":"Wong","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.033_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/01658107.2019.1660686","article-title":"Preliminary findings of a dedicated ocular myasthenia gravis rating scale: The OMGRate","volume":"44","author":"Wong","year":"2020","journal-title":"Neuro-Ophthalmology"},{"year":"2001","series-title":"International classification of functioning disability and health (ICF)","key":"10.1016\/bs.irn.2025.04.033_bib76"},{"key":"10.1016\/bs.irn.2025.04.033_bib77","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.20908","article-title":"Surrogate therapeutic outcome measures in patients with myasthenia gravis","volume":"37","author":"Zinman","year":"2008","journal-title":"Muscle & Nerve"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:58:14Z","timestamp":1760500694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443297229"],"references-count":77,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.033","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2025]]}}}